The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our progressing insight in human leukocyte antigen (HLA) class I and class II antigen processing and presentation mechanisms has improved the prediction by reverse immunology of novel cytotoxic T lymphocyte and T-helper cell epitopes within known antigens. Computer algorithms that in silico predict HLA class I and class II binding, proteasome cleavage patterns and transporter associated with antigen processing translocation are now available to expedite epitope identification. The advent of genomics allows a high-throughput screening for tumor-specific transcripts and mutations, with that identifying novel shared and unique TAA. The increasing power of mass spectrometry and proteomics will lead to the direct identification from the tumor cell surface of numerous novel tumor-specific HLA class I and class II presented ligands. Together, the expanded repertoire of tumor-specific T-cell epitopes will enable more precise immunomonitoring and the development of effective epitope-defined adoptive T-cell transfer and multi-epitope-based vaccination strategies targeting epitopes derived from a wider diversity of TAA presented in a broader array of HLA molecules.
Introduction
More than three decades after the discovery of major histocompatibility complex (MHC) restriction, 1 two decades after the first elucidation of MHC structure, 2 and 16 years after both the finding of MHC-specific peptide-binding motifs 3 and the identification of the first human leukocyte antigen (HLA) class I presented tumorspecific cytotoxic T lymphocyte (CTL) epitope, 4 ,5 T-cell-mediated immunotherapy of cancer has now outgrown its infancy. Nevertheless, trials in cancer patients have not shown consistent and high percentages of clinical successes, 6, 7 and immunotherapy of cancer is, with a single exception, 8 not yet a standard (adjuvant) therapy. The T-cell arm of the immune system is exquisitely equipped to eradicate virally infected cells by the recognition of short (8-11 aa.) peptides that are processed intracellularly from viral proteins and presented on MHC class I molecules. The similar use of T cells for the destruction of cancer cells that (over)express tumor-specific proteins is a long-standing challenge and has still to be exploited to its full clinical potential. Our rapidly accumulating understanding of the mechanisms involved in the adequate induction of anti-tumor immunity in patients is currently used for the design of more effective immunotherapeutic treatments. This will likely raise clinical success rates. For the development of effective T-cell-mediated cancer therapies it is crucially important that, next to an optimal immunostimulatory context, the tumor-associated antigens (TAA) and the T-cell epitopes contained in these proteins are properly chosen.
This review addresses T-cell-mediated immunotherapy of cancer in relation to the TAA and T-cell epitopes that can be used as targets. We will focus on the latest developments in the different strategies for the identification of both the tumor antigens and the CD8 þ and CD4 þ T-cell epitopes contained in these tumor-specific proteins. The 'reverse immunology' approach will be discussed in detail because it is the only strategy to identify novel T-cell epitopes in a systematic manner. Finally, issues related to the design of an effective well-defined multiepitope-based vaccine will be put forward.
T-cell-mediated immunotherapy for cancer, modalities and basic requirements for efficacy
Immunotherapy of cancer by T cells can be divided in passive adoptive T-cell transfer and active immunostimulatory vaccination strategies (reviewed in van der Bruggen and Van den Eynde 9 , Berzofsky et al. 10 and Melief et al.
11
). We provide a brief overview and will categorize adoptive transfer and active vaccination strategies in antigen-non-defined or antigen/epitope-defined forms, with a focus on epitope-defined vaccination.
Adoptive transfer of undefined tumor-specific or defined epitope-specific T cells
The only routine immunotherapy for cancer in the clinic to date is the infusion of donor lymphocytes after allogeneic stem cell transplantation in leukemia. This therapy is curative in significant percentages of patients. 8 The broad donor-derived CD4 þ and CD8 þ T-cell repertoire targeting a diversity of undefined (allogeneic) leukemia antigens is exploited in this setting. Remarkable clinical responses were observed in metastatic melanoma patients after adoptive transfer of autologous tumor-specific infiltrating lymphocytes (TIL) that were ex vivo expanded to high numbers. 12 The non-myeloablative conditioning regime in this trial may have contributed to the further expansion in vivo of the adoptively transferred T cells, by making space and also by the depletion of negative regulatory CD4 þ T cells. 13 Furthermore, the CD4 þ T-cell component in the transferred TILs has likely helped the memory CD8 þ T-cell population. 12 Because it is often hard to expand (clonal) tumorspecific CTL at high numbers ex vivo, efforts are undertaken to introduce tumor epitope-specific T-cell receptors (TCR) in peripheral blood lymphocytes (PBL) of the patient. 14 Promising clinical results were reported in patients with metastatic melanoma who were given autologous PBL retrovirally transduced with the TCR specific for the well-known MART-1 (aa. 27-35) HLA-A2-presented epitope. 15 TCR gene transfer has the advantage that the problem of expanding enough tumorspecific T cells is bypassed; however, targeting a single epitope may lead to antigen loss variants. Therefore, adoptive transfer of PBL transduced with multiple 'off-the-shelf' TCRs targeting CTL epitopes in different TAA is a logical and promising next step.
Vaccination strategies with undefined antigens
Irradiated autologous tumor cells or allogeneic HLA-matched tumor cell lines that are modified to express GM-CSF, IL-2 and other cytokines or costimulatory molecules have been used as vaccines.
In various clinical trials this type of vaccines has induced immune responses 16 and clinical responses have been reported. [17] [18] [19] [20] However, several disadvantages are connected to this strategy like the suboptimal direct antigen presenting capacity of tumor cells, absence of HLA class II presentation, uncertain cross-presentation and often the lack of autologous tumor samples needed for preparation of the vaccine. Other forms of vaccination with the full potential of undefined antigens from the targeted tumor are tumor lysates (loaded on dendritic cells (DCs) 21 ), heat shock proteins (HSPs) derived from the tumor and DCs transfected with amplified tumor mRNA. 22, 23 The main advantage of vaccination with autologous tumor cells, or tumor-derived lysates, HSPs or mRNA, is the presence of the full-undefined repertoire of relevant tumor antigens, including those with mutations that are unique in the individual tumor. In this sense, the strategies applying autologous tumor material are all personalized non-standardized vaccines that have to be produced for each patient separately. These therapies aim to induce T-cell responses against as much as possible (undefined) tumor-specific HLA class I (and in certain settings HLA class II) presented peptides.
Vaccination strategies with defined full-length TAA
Vaccinations with recombinant viral vectors or naked DNA plasmids encoding defined full-length TAA and vaccination with recombinant tumor proteins themselves have been applied in vaccines aiming to raise humoral and T-cell responses against the tumor expressing the antigen. Likewise, DCs electroporated with mRNA encoding full-length TAA are currently being optimized for clinical testing. 24 Vaccination strategies aiming to raise immunity to a full-length antigen have the advantage that the HLA haplotype of the individual patient does not need to be considered. On the other hand, and apart from the problems related to each mode of delivery (virus, DNA, mRNA, protein; reviewed in van der Bruggen and Van den Eynde 9 and Berzofsky et al. 10 ), vaccination with single-whole antigens has the important drawback that vaccine-induced immune pressure may induce escape through antigen loss variants of the tumor. In principle this could be circumvented by vaccination with multiple full-length-defined antigens (either in the form of DNA, mRNA 24 or protein).
Vaccination strategies with defined T-cell epitope containing synthetic peptides
Since the first identification of a defined tumor-specific CTL cell epitope, 5 the concept of immunizing cancer patients with synthetic peptide epitopes has been elaborated. Numerous clinical peptide vaccine trials have been conducted with sometimes promising results. The relatively poor immunogenicity of peptides per se requires them to be injected either together with adjuvants or loaded on DCs (reviewed in Cerundolo et al. 25 and Lesterhuis et al. 26 ). Further optimization of the peptide vaccination strategy is envisaged. 27 It is now firmly established that for robust and persistent CD8 þ T-cell responses a concomitant CD4 þ T-helper response is needed. [28] [29] [30] [31] Therefore, HLA class II presented tumor-specific epitopes are preferably incorporated in peptide vaccines to promote the CTL-mediated tumor destruction.
Important advantages of peptide vaccination are its defined nature and the easy manner to synthesize peptides by good manufacturing practice, enabling peptide vaccines to be used as pre-fabricated 'off-the-shelf' vaccines. Furthermore, modifications aiming at increasing the immunostimulatory context of the vaccine -like conjugation with synthetic Toll-like receptor ligands 32 -can easily be accomplished. Immunizations with a single (or only a few) CTL epitope(s) may induce outgrowth of antigen loss variants of the tumor. Therefore, peptide vaccines should preferably contain multiple HLA class I-presented CTL epitopes derived from different target antigens together with a tumor-specific HLA class II-presented CD4 þ T-helper epitope. The use of longer (30-mer) epitope-containing vaccine peptides that require processing which can only be accomplished efficiently by professional antigen presenting cells (DCs) has been shown beneficial. 33 The need for identification of defined tumor-specific CTL and T-helper epitopes Taking advantage of the full potential of the dormant anti-tumor T-cell immunity of the patient will in principle greatly enhance the clinical efficacy of immunotherapy. Numerous studies indicate that the anti-tumor T-cell repertoire is directed toward multiple CTL epitopes derived from different antigens. 20, [34] [35] [36] [37] [38] [39] Therapeutic exploitation of the complete potential of anti-tumor T cells can be achieved by adoptive transfer of expanded TILs or vaccination with autologous tumor cells (or lysates, HSPs, mRNA derived from the tumor). However, the cumbersome procedure to generate high numbers of autologous TILs, and often the failure to obtain tumor samples, severely hampers the application of these forms of non-defined personalized immunotherapy. In contrast, using epitope-defined forms of immunotherapy -either by adoptive transfer of PBL transduced with a specific TCR or by vaccination with (cDNA encoding) peptide epitopes -allows immunotherapy to be standardized with few fall out of patients. Targeting of defined epitopes requires the careful choice of the targeted TAA and their specific T-cells epitopes. This choice is dependent on both the antigen profile in the tumor and the HLA haplotype of the patients. Inducing T cells against multiple T-cell epitopes, both HLA class I and class II presented, in different TAA is strongly preferred. This will both reduce the risk of immune-driven selection of antigen loss variants of the tumor and will also awake a greater portion of the patient's anti-tumor T cells. For these reasons, and also for the monitoring of responses induced by any immunotherapy, it is needed to extensively define T-cell epitopes in TAA expressed in cancers of different histological origin.
TAA and their classification
For immunotherapeutic purposes, the most important criteria to classify TAA are: (1) broadness of expression (shared between patients and/or cancer types), (2) tumor specificity (absence of expression in healthy tissues) and (3) the function of the TAA in the oncogenic process and/or cancer survival. Additionally, (4) possible changes in turnover kinetics of the TAA are important to consider, 40 as for example in the case of p53. 41 With respect to broadness of expression, there is a first rough division in unique tumor antigens that are restricted to only an individual tumor in one patient -which for obvious reasons restricts their immunotherapeutic applicability -and the antigens that are shared between cancer patients. When combined with the criterion of tumor specificity, this results in the following often used classification.
(a) Unique tumor-specific antigens are resulting from mutations occurring in a single tumor of one patient. The first example of a unique point mutation was found in the melanomaassociated-mutated antigen-1 (MUM1) gene 42 41 Some antigens can be positioned in between two of the categories; for example, PRAME is widely expressed in various cancer types and, in contrast, in healthy tissues only at very low levels in adrenals, ovaries and endometrium, next to its expression in testis and placenta. 44 For further extensive listings of TAAs we refer to the literature 45 or databases available on the internet (for example at www. cancerimmunity.org).
Strategies for the identification of TAA
Identification of TAA can be accomplished with different experimental strategies. [46] [47] [48] [49] The discovery of MAGE-1 4 in the early 1990s as the gene encoding the first tumor-specific CTL epitope 5 is one of the pillars of tumor immunology. An autologous melanoma-specific CTL line was used to find the tumor-specific cDNA that encodes the recognized CTL epitope from a cDNA library derived from the melanoma. Subsequently, the minimal CTL epitope was identified by cDNA truncation and peptide recognition techniques. This classical strategy of expression profiling, which is often revered to as 'direct immunology' because it is based on natural immunity, has since then been applied for the identification of (among others) the MAGE, BAGE and GAGE families, 50, 51 Melan-A/MART-1, 52,53 tyrosinase 54 and gp100. 55 In a biochemical strategy, the CTL clone can also be used to identify the high-performance liquid chromatography (HPLC)-fraction of peptides isolated from the tumor cell surface that contain the epitope. Subsequently, mass spectrometry can identify the precise epitope sequence, and databank searches may lead to the identification of novel TAA. [50] [51] [52] [53] [54] [55] A key characteristic of both strategies is the use of an autologous tumor-specific CTL as the selection tool. The unknown tumorspecific CTL epitope is used as handle to identify the source protein, and, therefore, tumor protein discovery and T-cell epitope identification are intertwined in these strategies.
The serological identification of antigens by recombinant expression cloning (SEREX) strategy defines putative tumor antigens using patient-derived serum IgG antibodies to screen proteins expressed from tumor-derived cDNA libraries. 56 Tumor antigens identified by SEREX will likely contain CD4
þ T-helper cell epitopes because isotype switching from IgM to IgG implies the presence of specific help from CD4 þ T cells. The cancertestis antigen NY-ESO-1 57 is just one example of a large array of (putative) TAA that were identified by SEREX methodology. 47 With the rise of genomics and in silico data mining techniques, transcriptome analysis is currently used to detect tumor-specific expression profiles directly at the genetic level without the need for patient-derived T cells or serum (in more detail reviewed in Viatte et al.
58
). Various methods are used, like classical mRNA/ cDNA subtraction techniques, representational differential analysis, 59 ,60 differential polymerase chain reaction display and comparison of cDNA profiles obtained by serial analysis of gene expression, 61 DNAChip/microarray analysis [62] [63] [64] and expressed sequence tag databases. These studies often aim to identify expression profiles that can be used for the improved diagnosis, 64 classification 62, 63 or prognosis 65 of cancer. Tumor-specific expression of identified transcripts has to be confirmed at the protein level before immunogenicity studies are planned. The advent of the complete finished human genome sequence has enabled recent studies identifying mutational profiles in various cancers 66, 67 that reveal the number and uniqueness of cancerrelated mutations (within and between classes of cancer). Importantly, each mutation may give rise to (unique) cancerspecific T-cell epitopes. 37 
Selection of TAA for T-cell immunotherapy
Which TAA are most suitable as immunotherapeutic target? And how many TAA should be targeted simultaneously? These important questions are still being debated. First, the ideal tumor antigen target is widely expressed in different tumor types, enabling 'off-the-shelf' vaccines that are applicable in broad patient populations. Secondly, the function of the targeted TAA in the oncogenic process is highly relevant, although for several TAA not yet known. The phenomenon of immune escape by selection of antigen loss variants of the tumor is far beyond only theoretical consideration. 35, 38, 68 Therefore, TAA that either play a role in the oncogenic process or promote cancer cell survival are favorable targets. In this respect, the lineage-specific differentiation antigens are lower-ranked tumor antigens than purely oncogenic proteins like the HPV16-derived E6 and E7 proteins and the BCR-ABL fusion protein. 69, 70 Overexpressed anti-apoptotic proteins like survivin are interesting because downregulation or loss of such TAA would severely inflict the growth potential of the tumor cell. 71, 72 Likewise, the telomerase catalytic subunit (hTERT) is involved in the pathogenic process 73 and has a reported anti-apoptotic role. 74 Another tumor antigen for which a role in tumorigenesis and metastasis has been reported is PRAME. 65, [75] [76] [77] These tumor antigens (survivin, hTERT and PRAME) are widely expressed in different tumor types and constitute also for this reason attractive tumor antigens. However, it can not be excluded that therapy-induced immune pressure may give rise to selection of antigen loss variants, even of anti-apoptotic or tumor-promoting proteins, as has been observed in patients with melanomas expressing the melanoma inhibitor of apoptosis protein. 16 A third important consideration is the immunogenicity of the targeted tumor antigen. Tolerance to the non-mutated lineage-specific differentiation antigens (like gp100, tyrosinase and MART-1/Melan-A), which are selfproteins, may severely hamper an effective immune response against these antigens.
78,79 Such tolerance is likely affecting the immunodominant epitopes more than subdominant T-cell epitopes, which is a reason why the latter category of epitopes in these differentiation antigens has attracted considerable attention (see below). To circumvent both the selection of antigen loss variants and the tolerance to differentiation antigens, targeting of multiple antigens by polyvalent vaccines (or multispecific adoptive transfer) is essential. An additional advantage is that the full potential of the anti-tumor response in the patient is better exploited. The rule here would be targeting more antigens is better. Lately, driven by these problems, different groups have made an argument in favor of personalized immunotherapy targeting the unique antigens caused by mutations 66 that are often only present in the tumor of one patient. 37, 80, 81 These tumor antigens are purely tumor specific, and therefore not tolerogenic, and are believed to be often crucial to the oncogenic process. 37, 43 Furthermore, the natural immune response in some patients was found to be stronger against the unique antigens than the response against shared antigens.
36
Immunotherapies against non-defined tumor antigens such as vaccination with DCs transfected with tumor-derived mRNA 23 or tumor lysate-pulsed DCs are in fact personalized therapies that target both the shared and the unique antigens of each patient. However, the application of a defined patient-tailored immunotherapy will require identification of the unique antigens at the epitope level separately for each patient and meets with tremendous technical and logistic difficulties. 80 
Identification of tumor-specific T-cell epitopes
To date, a total of 180 HLA class I-restricted CTL epitopes and 75 HLA class II-restricted T-helper epitopes in shared TAA have been reported (according to the listing at www.cancerimmunity. org; update September 2006). Although this number of T-cell epitopes seems a reasonable start point for the design of defined immunotherapeutic vaccines, there is strong skewing to epitopes derived from antigens expressed primarily in melanoma and 75 (42%) of the HLA class I epitopes are presented in HLA-A2, leaving epitopes restricted by other HLA class I alleles underrepresented. This severely hampers the design and development of defined epitope-based vaccines targeting other tumors than melanoma, especially in patients lacking HLA-A2. Furthermore, the identification of HLA class II peptides recognized by T-helper cells, which are indispensable as help to mount efficient CD8
þ effector T-cell responses, [28] [29] [30] [31] has lagged behind ( Figure 1 ).
Identification of CTL epitopes starting with CTL of unknown specificity
The discovery of CTL epitopes has proceeded along two different experimental lines: either starting with a pre-existing CTL clone with unknown specificity (direct immunology), or departing from a predicted epitope (reverse immunology). In the first years all epitopes were identified by the direct immunology approach of expression cloning ( Figure 1 ). A patient-derived autologous tumor-specific CTL clone recognizing an unknown epitope was used to screen a tumor-derived cDNA library (mostly from melanoma), which is expressed in antigen-negative (tumor) cells. Subsequently, recognition of truncated variants of the epitope-encoding cDNA and mapping of synthetic peptides revealed the minimal epitope sequence. In this procedure, next to the unknown CTL epitope, the equally unknown source tumor antigen was often discovered together with the epitope (see above). [50] [51] [52] [53] [54] [55] The major drawback of this laborious strategy is the dependency on autologous tumor-specific T cells that are either generated in mixed lymphocyte tumor cultures (MLTC) or obtained as TIL. Such T-cell responses are generally scarce and the induction in MLTC is dependent on the availability of autologous tumor cell lines, which have been mainly obtained from melanomas. Furthermore, CTL responses from MLTC or TIL are mostly directed to immunodominant epitopes. In recent years, the direct approach has been adapted for the identification of epitopes in known antigens without the need for autologous tumor cell lines. As elaborated by Chaux et al., 82 TAA artificially expressed in DCs were used for the generation of autologous CTL clones specifically recognizing unknown Identification of T-cell epitopes for cancer immunotherapy JH Kessler and CJM Melief epitopes derived from the transduced antigen. Peptide-mapping experiments then again revealed the exact epitope sequence. By virtue of the natural CTL response that is used this method as well will result in the identification of mostly immunodominant epitopes, and a systematic search for novel epitopes is impossible. An alternative biochemical approach for defining the unknown specificity of tumor-reactive CTL, which are either induced against tumor cells 83, 84 or for example against peptides eluted from tumor cells, 85 starts with the immunoaffinity purification of the HLA class I -peptide complexes from the relevant tumor cell. The peptides are subsequently isolated and fractionated by (multiple rounds of) HPLC to reduce the complexity of the peptide pool. Pinpointing the fraction that contained the epitope through recognition by the CTL together with tandem mass spectrometry (MS/MS)-mediated sequencing of the peptides in that fraction identifies the precise peptide sequence. [83] [84] [85] [86] [87] [88] Subsequently, database searches may identify the unknown source antigen. [85] [86] [87] [88] A particular advantage of this strategy is that it may identify post-translationally modified epitopes 89, 90 (or special epitopes generated by protein/peptide splicing 48, 49, 91 ). Still another way to analyse the specificity of pre-existing CTL clones is the application of synthetic peptide libraries to search for reactive mimicry epitopes. The natural epitope may subsequently be identified by screening recognition of substitution analogs, defining a recognition motif and database searching. 92 The combination of library screening-deduced T-cell recognition motifs in the peptide and MS/MS sequencing of eluted peptides has also been exploited to identify a novel mouse CTL epitope. 87 
Identification of predicted CTL epitopes by reverse immunology
Since the first finding of HLA-specific peptide-binding motifs in the early 1990s, 3 our emerging knowledge of intracellular HLA class I ligand generation has enabled the screening of known TAA for contained peptides that are predicted to be cell surface expressed. Predicted HLA class I ligands can be tested for their immunogenicity by raising CD8 þ T cells against the exogenously loaded peptide. Subsequently, peptide-specific CTL are tested for their recognition of tumor cells expressing the relevant TAA and restriction element to prove the natural presentation of the CTL epitope. The basis of this indirect strategy for CTL epitope identification, which was coined 'reverse immunology', is that an initial epitope prediction phase is followed by an epitope validation phase (Figure 2) . Nowadays, approximately 40% of the CTL epitopes in shared TAA (Figure 1) , and also numerous CTL epitopes in viral and microbial antigens, have been identified via the reverse immunology strategy. The advantage of reverse immunology is that it is the only strategy that can be used to systematically search novel epitopes, including subdominant ones, in known proteins and presented in any HLA molecule of interest. Both the prediction phase and the validation phase of reverse immunology have their own difficulties and weaknesses, although significant improvements have lately been implemented.
Prediction phase of reverse immunology
The prediction phase of the reverse immunology approach takes advantage of our growing knowledge concerning the intracellular generation of peptides presented in HLA class I molecules (reviewed in Kloetzel and Ossendorp 93 and Saveanu et al.
94
). These HLA class I ligands, which are called CTL epitopes only when immunogenic, are produced from either full-length protein molecules tagged for destruction or from shorter defective ribosomal products 95 by a process that can be divided in three main events. The first event that defines a CTL epitope is the release of the epitope or epitope precursor from its natural flanking regions in the protein through enzymatic digestion by cytosolic peptidases. Abundant multicatalytic proteasomes are considered responsible for the generation of the C terminus of the vast majority of CTL epitopes. [96] [97] [98] The generation of the N terminus of a CTL epitope, on the other hand, is much more flexible because several N-terminal exo-peptidases reside in the cytosol and endoplasmic reticulum (ER) and these trimming enzymes have the capacity to shorten an N-terminal elongated epitope precursor to its precise length. In contrast, C-terminal trimming has not been reported. The cytosolic protein degradation is a general protein turnover process that basically results in recycled amino acids. 99 Cytosolic endopeptidases and aminopeptidases contribute to the further degradation of proteasomal digestion products. Escape of peptides from the cytosol into the ER via the transporter associated with antigen processing (TAP) is, therefore, a second important event required to preserve peptides from further cytosolic degradation. In the ER, peptides may assemble with HLA class I heavy and light chains, which is the third event indispensable for cell surface presentation. The chemical complementarity of the so-called anchor residues in the peptide with residues in the main pockets of the peptidebinding groove of the HLA molecule determines how efficient a peptide will bind. The combination of primary anchor residues (mostly at position two and the C-terminal position) and secondary anchors in the peptide that are required for efficient binding is defined in the peptide-binding motif for each HLA class I molecule. 3 The extensively polymorphic HLA class I molecules -each individual expresses up to six HLA class I molecules, of which hundreds of variants are known (see www.anthonynolan. com/HIG and Robinson et al.
100
) -can be grouped in several HLA class I supertypes 101 with overlapping binding motifs, but each molecule may have its own fine specificity.
The determination of peptide binding motifs for the prevalent HLA class I molecules has allowed the in silico screening of TAA by computer algorithms for aa. sequences with predicted binding capacity. Various HLA class I binding algorithms have been developed of which the BIMAS algorithm 102 and the SYFPEITHI algorithm 103 are freely accessible and currently the most widely used (see Table 1 Figure 2 Flow chart of the reverse immunology approach for CTL epitope identification.
Identification of T-cell epitopes for cancer immunotherapy JH Kessler and CJM Melief independently or the overall peptide structure, but are all extremely valuable to select the small percentage of peptides with potential binding capacity. 106 Guidelines for validation and comparisons between the different algorithms have been made, 106, 107 and significant differences in the predictions often occur. As an example, we calculated percentages of overlap between predictions by the BIMAS and SYFPEITHI algorithms for the best 20, 50 and 100 predicted peptides from full-length PRAME (length 509 aa.) for three prevalent HLA class I molecules. For the best 20 predicted binders, the overlap may be as low as 25% (Table 2a) . Therefore, from a practical point of view, the combination of two or more methods is advisable to reduce the number of nonselected peptides with binding capacity.
Experimental verification of actual binding capacity is strongly preferred, because the ranking of the predictions does not perfectly correlate with the actual binding measurements and false positive prediction of binding occurs 108 (exemplified in Table 2b ). For instance, we found the 13th predicted 9-mer PRAME peptide (PRA 44À52 ) actually lacks binding capacity for HLA-A*0201, whereas the 16th predicted binder (PRA 435À443 ) bound with highest affinity (Table 2b) . HLA class I binding assays exist in various forms (reviewed in Viatte et al.
58
), and can be divided into cell-free assays (using soluble HLA) versus cellular assays (using HLA class I molecules on the cell surface 108 ), and competitive assays (resulting in semi-quantitative data) versus assays that do not use a labeled reference peptide and are therefore quantitative. Next to verification of binding capacity, Method and additional information are found on webpage.
Identification of T-cell epitopes for cancer immunotherapy JH Kessler and CJM Melief
the stability of peptide binding can be measured. Highly stable peptides have been shown to be more immunogenic. 109 
Improved CTL epitope prediction by verification of proteasomal processing and TAP translocation
The tumor-specific CTL epitopes that were identified by reverse immunology in the first years (until 2001) were predicted by taking into account only the HLA class I peptide binding capacity. [110] [111] [112] [113] However, it was observed that numerous CTL that were raised against high-affinity binding peptides did not recognize tumor cells expressing the relevant TAA and restriction element. [114] [115] [116] [117] [118] A major reason for this was the lack of intracellular generation of predicted peptides by the processing machinery. Therefore, we decided to incorporate in the prediction the proteasome-mediated digestion analysis of long (approximately 30-mer) peptides encompassing the class I binding peptide with its natural flanking regions. 119 This allowed us to judge the C-terminal liberation of 19 high-affinity HLA-A2 binding peptides in TAA PRAME. Only four of these 19 peptides were efficiently excised after their C terminus by the proteasome. Therefore, the other peptides were considered to be likely not produced intracellularly and laborious T-cell inductions against these peptides could be omitted. 119 This optimization of the prediction phase has greatly enhanced the accuracy of epitope predictions and has since then been applied successfully in studies identifying CTL epitopes in TAA 69,120-123 and autoimmune antigens. [124] [125] [126] Four computer algorithms, which are based on different computational methods, are currently freely available via the internet for the prediction of proteasomal cleavages: MAPPP/ FragPredict, 127 PAProC, 128 NetChop 129 and Pcleavage 130 ( Table 1) . Proteasomes cleave abundantly at certain sites and cleave much less abundant or do not cleave at other sites. However, due to the broad specificity of the proteasome, the stochastic nature of proteasomal digestion 129, 131 (overlapping fragments are often found in the experimental systems 69, 119, 131 ), and (partly) undefined influences of distant residues on cleavage efficiency, a qualitative and quantitative accurate prediction of proteasomal digestion sites is very complicated. In general, predictions may still result in a high number of improperly predicted cleavage sites. 119 Therefore, experimental determination of proteasome-mediated digestion is needed to reliably select peptides that are C-terminally liberated (see also below). An extra level of complexity here is the different forms in which proteasomes occur. Some CTL epitopes are preferentially made by immunoproteasomes, 132 which are expressed in professional antigen presenting cells 133 and contain variant catalytic subunits with slightly different catalytic activity, 134 and other epitopes are preferentially made by constitutive proteasomes, 135, 136 although most epitopes are liberated by both types of proteasomes. To cover both categories of epitopes, predictions and experimental verifications should use (in silico or in vitro) both types of proteasomes. Instead of first performing HLA class I binding assays, 119 the proteasomal digestion pattern can also be determined first. 122 This reflects the physiological mechanistic order and has the advantage that binding of only those peptides that are C-terminally liberated by a major cleavage site needs to be verified experimentally.
Translocation of peptides into the ER via TAP is also an important event in the class I antigen presentation pathway. However, the specificity of the TAP heterodimer for peptides is much less selective because peptides meant to bind in all possible HLA class I molecules should be translocated into the ER. Specificity of TAP even seems to have evolved to fit the specificity of the proteasome. 137 Despite that, differences in translocation efficiencies between peptides exist 138 and TAP affinity has impact on HLA class I presentation. 139 Thus reasoning, in silico TAP translocation prediction algorithms have been developed [140] [141] [142] (Table 1) to incorporate TAP translocation efficiency in the overall HLA class I ligand prediction. However, a problem related to determination of TAP translocation efficiencies (in silico or in vitro) is the N-terminal trimming that can occur both in the cytosol and in the ER. Therefore it is not a priori known which peptides should Peptides were predicted from full-length PRAME. Prediction by SYFPEITHI algorithm of 9-mer peptides derived from PRAME binding in HLA-A*0201. 
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be tested. In general, TAP translocation efficiency, either predicted or experimentally verified, has until now been incorporated in only few reverse immunology studies identifying novel CTL epitopes. 125 Recently, integrated in silico CTL epitope predictions have been developed that combine predictions of proteasomal cleavages, TAP translocation and HLA class I binding (Table 1) . In addition, an algorithm was developed that directly predicts CTL epitopes using large data sets of T-cell epitopes and nonepitopes as training data for the algorithm (CTLPred). 143 We concisely tested the performance of the five integrated algorithms (MHC-Pathway, 144 WAPP, 145 NetCTL, 146 IEDB and EpiJen 147 ) using as test-set the 64 nonameric peptides from our PRAME study that were in vitro tested for their HLA-A2 binding and proteasomal liberation to identify two CTL epitopes 119 ( Table 3 ). The two published epitopes were predicted in the 10 best ranked predicted epitopes by four of the five algorithms. MHC-Pathway, which did not rank the PRA 100À108 epitope in the top-10, instead, correctly predicted PRA 301À309 (which is a natural epitope; our unpublished results). The combined algorithm from the 'immune epitope database and analysis resource' (IEDB) 148 predicted all three epitopes. On the other hand, importantly, all five predictions contained a considerable number (450%) of falsely predicted epitopes, mainly because the C terminus was (in vitro) not generated by the proteasome (Table 3 ). This implies that experimental verification of proteasomal cleavages is still strongly recommended to improve the selection of putative epitopes. Another practical weakness of the integrative algorithms is that they mostly allow the prediction of only nonamers (with exceptions for certain alleles), and their coverage of prevalent HLA class I alleles is incomplete.
Generally speaking about CTL epitope prediction, the challenge is to find a balance between the reduction in work in the prediction phase when predictions are accomplished solely in silico (without experimental verification) on the one hand and on the other hand, the loss in quality of the final prediction, which will lead to more laborious work and reduced success rates (more and failed T-cell inductions) in the validation phase. This balance may depend on the precise research question, including the length of the source protein under study: the longer the protein, so much the better the chance that top scoring-predicted epitopes will be genuine epitopes.
Validation phase of reverse immunology
In the validation phase of the reverse immunology approach, the natural presentation and immunogenicity of the putative epitope should be demonstrated. In principle, two roads are open (Figure 2) . First, the biochemical purification of HLA-peptide complexes -from cells expressing the relevant TAA and HLA class I molecule -followed by the mass spectrometric search for the predicted peptides in the eluted HLA class I-bound ligands (the 'predict-calibrate-detect' method; see below). 149, 150 However, this method validates cell surface expression of predicted HLA class I ligands but not their immunogenicity. Therefore, in the vast majority of studies, the prediction phase is directly followed by the induction of (naïve) T cells against the exogenously loaded predicted epitope. Peptide-specific T cells are then used as tool to test the natural presentation of the epitope. T cells have mostly been induced in vitro using human PBL from healthy donors. 69, 119 Furthermore, PBL 120, 151 or TIL 122 from patients with the relevant tumor antigen and restriction element have been used. An alternate approach is the induction of T-cell responses in HLA class I transgenic mice. 152 Peptidespecific T cells should be used at the clonal level to enhance Prediction using the ARB method (see website; Table 1 ).
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specific responses and to reduce aspecific background recognition of target cells that lack tumor antigen or restriction element. Next to tumor cells expressing the relevant TAA and HLA class I molecule, target cells should preferably include transfected target pairs with or without the tumor antigen and lacking or expressing the relevant HLA molecule. This enables exclusion of aspecific recognition effects by T-cell clones that may be crossreactive to irrelevant antigens. The sensitivity of the CTL clone for the peptide should be high, which is to be determined with peptide titration, before a definitive judgement of the natural presentation of the epitope can be made. While CTL recognition of properly chosen target cells will prove the natural presentation of the predicted epitope, it should be noted that, in principle, sometimes a length variant of the predicted epitope (with comparable binding capacity) may be the actually recognized peptide. Is such a case suspected, then MS/MS is required to determine the exact aa. sequence of the epitope variant after its isolation from the cell surface (Figure 2 ).
Efficiency of reverse immunology
For an all-over judgement of the efficiency of the reverse immunology approach it is important to note that prediction of HLA class I ligands relies on the selection of peptides that are enzymatically generated, survive further cytosolic degradation by translocation into the ER and have high class I binding affinity. On the basis of kinetic data it has been calculated that even more than 99% of intracellular peptides are destroyed before encountering TAP. 99 Consequently, the production of class I ligands is an inefficient process. A low number of predicted epitopes, therefore, is a sign of strength of the prediction phase, provided that these peptides are genuine epitopes. Our experience 69, 119 and that of others 126 is that the extended prediction procedure including proteasomal digestion analysis, which selects peptides with high class I binding affinity that are C-terminally liberated by an abundant proteasomal cleavage site, very accurately predicts CTL epitopes. Obviously, selection of peptides according to lower stringent selection criteria may result in the prediction of non-existing class I ligands. Factors that may severely hamper the validation of putative epitopes are the lack of peptide-specific precursor T cells in the repertoire of the chosen donor, which may be caused by tolerance in the case of differentiation antigens, the possibly low sensitivity of the induced CTL, and unfavorable growth characteristics of CTL clones. To improve success rates, several adaptations have been made in the T-cell induction protocols 153 and procedures were developed to accelerate expansion of specific CTL by selecting cytokine-secreting or tetramer-positive T-cell populations. 122 An issue related to efficiency is the question how often peptides are falsely negatively predicted, in other words: how many epitopes are missed? Apart from selection criteria that may be chosen too stringent, false negative predictions may result from intrinsic weaknesses. First, peptides with high binding affinity may be missed because the algorithms are not completely covering all possible positive and negative effects on binding, and some peptides lacking the canonical binding motif, 154 which will score low in binding prediction and will not be selected (false negative prediction), may have high actual binding capacity (an example is shown in Table 2b : peptide CTWKLPTLA lacks the canonical HLA-A2 anchors at position two and the C terminus). Another important point is that to date the majority of binding prediction algorithms allow only predictions of nonameric and decameric peptides for most HLA class I molecules, despite a substantial number of class I ligands being 11-mers (for example, 25 out of 298 HLA-A2 ligands in the SYFPEITHI database 103 ) and still longer CTL epitopes have been reported. [155] [156] [157] Secondly, our still incomplete understanding of antigen processing will also contribute: recent evidence indicates that an unknown percentage of CTL epitopes are C-terminally liberated by a proteasome-independent mechanism. 158, 159 It has been calculated from experimental digestion results, for instance, that the likelihood of a proteasomal cleavage after a lysine is very low, although a high number of (mainly HLA-A3 presented) epitopes own a C-terminal lysine. 144 This is suggestive for a supplementary enzyme system. 159 Thus, verification of in vitro proteasomal C-terminal generation predicts the intracellular generation of most class I ligands, but will miss those that are C-terminally liberated by other enzymes. An additional category of class I ligands being missed by reverse immunology are peptides that are post-translationally modified 89, 90 or produced intracellularly by uncommon mechanisms like peptide splicing. 48, 49 In summary, when applying experimental verifications with stringent selection criteria in the prediction phase, reverse immunology is extremely well suited to successfully predict HLA class I-presented ligands of which the immunogenicity is sometimes hard to confirm (or absent) due to absence of specific T cells. On the other hand, reverse immunology will miss an unknown percentage of ligands/epitopes of which the restriction may be biased to certain alleles (HLA-A3). Finally, to successfully identify ligands for a certain HLA class I molecule, the length of the source antigen is obviously a relevant factor. For instance, in a comprehensive analysis, we found only four HLA-A2-restricted epitopes in PRAME, which is 509 aa. long. 
Identification of HLA class II-presented T-helper epitopes
Like CTL epitope identification, the identification of HLA class II-presented T-helper cell epitopes can either start with a CD4 þ T cell recognizing an unknown epitope or may depart from T-helper cells which are induced against either predicted epitopes or a complete set of overlapping peptides in a reverse immunology setting (Figure 1) .
In vivo sensitized CD4 þ T cells that recognize a tumor antigen have been employed to identify epitopes by expression cloning. 160, 161 Contrary to HLA class I ligands, peptides binding in HLA class II are relatively long, and different length variants of a T-helper epitope are often recognizable by a single-T-helper clone. This characteristic has often advantageously been exploited to screen the T-helper cell reactivity against a complete set of overlapping peptides of a TAA using responder CD4 þ T cells that were derived from either patients or healthy donors. Subsequently, peptide-specific T-helper clones were tested for their recognition of endogenously processed TAA to validate the epitope. [162] [163] [164] The application of in silico algorithms for the prediction of HLA class II-presented epitopes has lagged behind the use of predictions for CTL epitope identification. Binding requirements for peptides in HLA class II molecules are much less restricted than for class I molecules. Thus, the HLA class II binding motifs share a certain degree of degeneracy, and prediction of binding is less straightforward. Furthermore, the peptides bound in HLA class II have a broad length spectrum (9-25 aa.), and class II antigen processing pathways are only incompletely defined making any assessment of processing uncertain. In addition to the classical endosomal-lysosomal pathway of exogenous and transmembrane proteins, alternate and partially overlapping routes for class II ligand generation exist in the cytosol. 165 Both proteasome-dependent and proteasome-independent cytosolic generation of class II ligands derived from either exogenous or endogenous sources have been reported. [166] [167] [168] [169] [170] Furthermore, HLA class II antigen processing can differ depending on the route of delivery of exogenous antigens 167 and the precise antigen presenting cells in which it takes place. 170 Despite this complexity in the processing, several HLA class II binding algorithms have been developed 103, [171] [172] [173] (listed in Table 1 ). The degeneracy of HLA class II binding motifs allows the search and prediction of promiscuous pan-class II binding peptides, which are obviously more widely applicable for vaccine development. HLA class II peptide binding predictions have successfully led to the identification of promiscuous T-helper epitopes in among others: NY-ESO-1, 174 TRP-2, 175 hTERT, 176 and Melan-A/MART-1.
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Identification of HLA class I and class II ligands by MS/MS
As discussed above, starting from pre-existing CTL with unknown or known specificity, the combination of microscale liquid chromatography coupled to MS/MS with functional immunoassays has been used for the identification or confirmation of tumor-specific CTL epitopes, respectively. [83] [84] [85] [86] [87] [88] [89] Without the availability of an epitope-specific T cell, MS/MS can also be applied for the validation of predicted HLA class I ligands (Figure 2 ). This alternative reverse immunology strategy was coined the 'predict-calibrate-detect' (PCD) method. 150, 152 Predicted ligands are synthesized and used for the calibration of an HPLC -mass spectrometry system to identify co-eluting natural ligands of identical mass of which the precise identity is then verified by MS/MS sequencing. In this manner, Stevanovic and colleagues identified class I ligands from p53, CEA and MAGE-A1 in peptides extracted from tumor tissue or tumor cell lines. 149, 152 Although technically demanding, the PCD method advantageously does not depend on the often cumbersome generation of peptide-specific CTL clones and allows the identification of low abundant peptides. It is, therefore, a secure intermediate station in the identification of CTL epitopes. The immunogenicity of the ligands still needs to be determined by T-cell inductions. 152, 178 With the aim to identify as many novel tumor-specific HLA ligands as possible in a single-tumor sample, mass spectrometric ligand identification has been coupled to gene expression profiling to reveal antigens (over)expressed in the tumor, but not in healthy tissue from the same patient. 81 This method has recently been used to identify HLA class I ligands derived from both universal and novel renal cell carcinoma-associated antigens. 179 These HLA class I ligands were in part unique for the patient and can therefore in principle be used in a personalized therapy.
Subtractive mass spectrometric approaches have been used for the direct identification of differentially expressed HLA class I and class II ligands with the aim to identify disease-related (for example TAA-derived) ligands. Peptides in HLA-DR4 from an diabetes auto-antigen were identified by mass spectrometric comparison of HPLC-fractionated peptides purified from either untreated cells or cells that endogenously processed the antigen after it was delivered via a lectin-based method. 180 Lemmel et al. 181 were the first to use differential stable isotope labeling (for example differential acetylation) of HLA class I-bound peptides extracted from colon carcinoma versus regular colon tissue to quantify their ratio by mass spectrometry. A variant of this subtractive analysis applied differential stable isotope labeling to two isoforms of a meningococcal outer membrane protein before their uptake by DCs, again to create a so-called mass-tag (resulting in spectral doublets) that simplified the comparisons between HLA class II ligands extracted from the two sources. 182 The same group applied metabolic labeling by culturing virus-infected cells with stable isotope-labeled amino acids. Comparisons between the labeled peptides extracted from infected cells and the unlabeled peptides from noninfected cells have led to the identification of viral and infectioninduced HLA class I ligands. 183 These pairwise comparative methods of mass spectrometric analysis could also be applied to tumor antigens.
As normally tumor cells do not express HLA class II, the direct isolation of class II-bound peptides from tumor cells was not considered feasible. Instead, several strategies have been used to target antigens into antigen presenting cells. 180, 184, 185 A recent study, however, reports the successful identification of (tumorassociated) HLA class II ligands from dissected primary tumor samples that were found to express HLA class II. 186 The advent of proteomics in the identification of HLA-bound ligands is typically technology driven. 187, 188 With the development of improved mass spectrometry technologies that are more sensitive and more accurate, the identification by MS/MS of many more peptides in one sample is now possible. Highthroughput MS/MS analyses in an automated data-dependent mode followed by database searches allow the identification of a significant percentage of the full HLA-bound 'ligandome' of a sample without prior focusing on predicted epitopes. It is already now possible to identify up to 3000 peptides per allele from one cell line (P.A. van Veelen, personal communication, unpublished data). Further improvements in sample preparation and separation techniques, and data analysis will still boost the results. 189 This will lead to the identification of novel tumorspecific HLA class I ligands (likely immunogenic T-cell epitopes) derived from both known and as yet unknown universal TAA and also from unique mutated antigens. Basic insights and the development of anti-cancer immunotherapies, which may include individualized vaccinations with defined tumor-specific epitopes that are partly unique for the patient, 80 will greatly benefit from these developments.
The need to define more T-cell epitopes: multi-epitope-based cancer immunotherapy
Several reasons exist to further broaden the repertoire of defined tumor-specific CTL and T-helper cell epitopes. First of all, the immunomonitoring of cancer patients treated with any T-cellmediated therapy is required to assess the effectiveness of the treatment. Monitoring of T-cell responses is mostly accomplished ex vivo by measuring T-cell populations with tetramers of the tumor epitope or by measuring specific cytokine (e.g. IFNg) production upon stimulation with defined T-cell epitopes. 190 In the case of vaccination with undefined antigens (tumor cells, tumor lysates or e.g. tumor cell derived mRNA) or full-length TAA (irrespective of the vehicle), the monitoring of T-cell responses against multiple T-cell epitopes will better reveal the effects induced by the therapy. Even in the case of vaccination with a single minimal epitope, immunomonitoring of a T-cell response induced by the so-called 'antigenic spread' against a non-vaccine CTL epitope that is expressed on the tumor may be necessary to correctly assess the efficacy of the therapy. 191 A strong argument can be made for a defined multi-epitope and multi-TAA-directed T-cell immunotherapeutic approach, either by using adoptive transfer of PBL transduced with multiple TCR or by applying vaccination strategies. Targeting multiple TAA will enhance the barrier against escape of antigen loss variants of the tumor and will exploit more fully the anti-tumor T-cell potential of the patient (in the case of vaccination). Loss of HLA class I molecules on tumor cells, which can be another reason for immune escape, is often restricted to only one or a few alleles. 192 Targeting multiple epitopes restricted by different class I molecules of the patient will circumvent such an escape mechanism. Where the latter goals may also be reached by vaccination with multiple full-length TAAs (expressed in the tumor), it has been shown that the use of optimal epitopes can induce immune responses with increased potency compared with the response induced by the same epitopes in the context of the full-length protein. 193 Given the pivotal role of CD4 þ T cells in promoting the primary and secondary CD8 þ T-cell responses through the induction of DC maturation and the production of cytokines, [28] [29] [30] [31] the inclusion of T-helper epitopes in a multiepitope-based vaccine will have strong beneficial effects. Furthermore, vaccination with minimal CTL peptide epitopes, unless administered on DCs, may cause T-cell tolerance through their systemic spread and presentation on non-professional antigen presenting cells. 194, 195 To circumvent this, vaccines should contain longer epitope-containing peptides that require processing which can only be accomplished efficiently by professional antigen presenting cells (DCs).
When enough CTL and T-helper epitopes -derived from different TAA and presented in various prevalent HLA molecules -are identified, it would be feasible to combine these epitopes in a defined epitope-based vaccine (as peptide vaccine or, for example, recombinant 'string-of-bead' viral delivery system 196 ) that is tailored to the TAA expression pattern and HLA haplotype of each patient. We found that vaccination with longer (35-mer) peptides, containing both CTL and T-helper epitopes in their natural protein context, leads to a far more robust CD8 þ T-cell response and therapeutic immunity in a mouse model. 33 Both the induction of a concurrent CD4 þ T-cell response and the restricted processing and presentation of the long peptides only by professional antigen presenting cells contributed to this enhanced efficacy. 197 Vaccines based on defined epitopes have the additional advantage that the binding and TCR recognition characteristics of the epitopes can be optimized by aa. replacements. In the case of differentiation TAA, tolerance against the immunodominant epitopes is expected, and these are therefore not first choice. The subdominant epitopes, however, mostly have a lower binding capacity rendering them less immunogenic. Designing modified analogs of the epitope, also called altered peptide ligands, with improved binding characteristics can be used to efficiently recruit a non-tolerized T-cell repertoire. 198, 199 However, care should be taken that vaccination with epitope analogs does not induce CTL that are incapable of recognizing tumor cells as has been observed in patients vaccinated with optimized variants of MART and gp100 CTL epitopes. 200 Obviously, any epitope contained in epitope-based vaccines should be thoroughly checked for its natural processing and cell surface presentation to avoid responses against so-called cryptic epitopes that are not presented on the tumor cells. 201, 202 
Conclusion
With the advent of genomics and proteomics, the last years have seen the introduction of large-scale high-throughput screening methods, both for tumor antigen discovery and T-cell epitope identification.
It is expected that the rapidly increasing power of mass spectrometric techniques will have a tremendous impact on the unraveling of the cancer-specific HLA-bound 'ligandome'. The identification of HLA class I ligands by reverse immunologybased predictions may eventually be bypassed by direct identification of cell surface-presented peptides with mass spectrometry. T-cell responses against such identified proven HLA ligands are then needed only to test the immunogenicity of the ligand, and not any longer to validate its cell surface expression. Direct sequencing by MS/MS will identify, next to numerous novel 'conventional' ligands, also HLA class I ligands owning non-canonical binding motifs, extraordinary length or post-translational modifications that may have been produced by non-conventional enzymatic mechanisms, possibly even in a proteasome-independent manner. With the identification of more CTL and T-helper cell epitopes derived from more TAA expressed in a wider repertoire of cancers presented in HLA class I and class II molecules covering the full haplotype diversity, we will in principle be able to develop multi-epitope, multi-TAA-targeting immunotherapies that are applicable in a higher percentage of patients and that will exploit a more significant percentage of the dormant anti-cancer T-cell response in the patient. Together with important and necessary upcoming improvements in the immunogenic context of vaccines and adoptive transfer this is expected to result in a significantly enhanced efficacy of anti-cancer immunotherapies.
